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Introduction
Prostaglandins such as PGE 2 are autocrine and paracrine lipid mediators that trigger a wide variety of signals (Miller 2006) . These signals are terminated by the metabolism of PGE 2 (Ferreira and Vane, 1967; Hamberg and Samuelsson, 1971; Schuster, 1998) . Oxidative inactivation of PGE 2 is catalyzed by 15-hydroxyprostaglandin dehydrogenase (15PGDH; E.C.
1.1.1.141), which is localized in the cytoplasm (Casey et al., 1980; Casey et al., 1982; Kobayashi et al., 1992) . Thus, PGE 2 has to be translocated from the outside to the inside of cells in order for it to be metabolized to PGE 2 metabolites (PGE 2 -M), including 15-keto PGE 2 . The prostaglandin transporter (PGT), a member of the organic anion transporter family (OATP) (Kanai et al., 1995) , mediates the energetically active influx of PGE 2 (Chi et al., 2006) , accounting for almost 100% of PGE 2 internalization (Kanai et al 1995; Chi and Schuster, 2010) . In cell culture, we have demonstrated that PGT-mediated PGE 2 influx is required, and is rate-limiting, for PGE 2 metabolism (Nomura et al., 2004) . In accord with these finding, we have reported that global deletion of PGT in mice results in elevated systemic PGE 2 and reduced plasma PGE 2 -Mlevels (Chang et al., 2010) . Taken together, these data indicate that PGT plays a central role in PGE 2 metabolism and signal termination.
As an experimental tool, however, such a genetic approach has limitations, since PGT global knockout mice cannot survive past postnatal day 1 due to patent ductus arteriosus unless they are rescued by administration of indomethacin to the mother before parturition (Chang et al., 2010) . A chemical agent that specifically inhibits PGT would be advantageous, both to rapidly assess PGT functions in a variety of different physiological and pathophysiological models, and to further investigate the role of PGT in controlling PGE 2 metabolism and thus signaling.
This article has not been copyedited and formatted. The final version may differ from this version. Previously, we reported a new class of PGT inhibitor obtained by screening a small molecular library (Chi et al., 2006) . The best hit of that screening was T34 (Fig. 1) , with a binding constant (K i ) of 3.7 µM. Although the K i of T34 on PG uptake is almost identical to that of bromcresol green (Bito and Salvador, 1976a, Kanai et al., 1995) , T34 has considerable potential to be optimized into a high affinity inhibitor by virtue of its three side chains, R 1 , R 2 , and R 3 (Fig. 1) . Accordingly, here we conducted extensive structure-activity relationship (SAR) studies starting with the T34 platform, which allowed us to obtain T26A ( Fig. 1) , a competitive inhibitor of PGT, with a K i of 378 nM (10 fold more potent than T34). Importantly, we show that T26A is specific for PGT, and in whole animal studies document the ability of T26A to systemically inhibit PGE 2 metabolism.
This article has not been copyedited and formatted. The final version may differ from this version. 
Methods
Materials. The cell lines used in this study were wild type MDCK (WT-MDCK) cells that do not express endogenous PGT, and MDCK cells stably transfected with the green fluorescent protein-tagged rat PGT (PGT-MDCK) as generated in our laboratory (Endo et al., 2002 Synthesis of small molecule compounds. The small molecule triazine compounds were synthesized following reported procedures (Min et al., 2007) .
Inhibitory effects of small molecules on PGT activity. These procedures are as described previously (Chi et al., 2006 K i values of inhibitors. The procedures are as described previously (Chi et al., 2006 were determined by methods similar to those previously described (Chi et al., 2006) , and the K i of T26A to OAPTc was calculated accordingly (Chi et al., 2006) .
T26A effects on cyclooxygenase (COX) activity. The effects of T26A on the activities of ovine COX1, ovine COX2, and recombinant human COX2 enzymes were measured using a kit from Cayman Chemical (catalogue #, 560131). was inserted into the right carotid artery and connected to a syringe for blood withdrawal.
Thereafter, 200 μL of vehicle (4% DMSO + 4% cremophor) or 25 mM T26A were injected into the jugular vein, 13 minutes later 1 mL of blood was withdrawn from the carotid artery, and then 100 ng PGE 2 in 200 µL saline was immediately injected intravenously. The time at which PGE 2 was injected was considered 0 minutes in Fig. 8C and 8D. Thereafter, 1 mL arterial blood was withdrawn at 1, 3, 5, and 10 minutes. 10 µM indomethacin was added to blood immediately after withdrawal to block further PG synthesis, and the blood was immediately centrifuged at 15,000 rpm and 4˚C for 15 minutes. Plasma was collected and kept at -80˚C for PGE 2 and PGE 2 -M measurements. PGE 2 and PGE 2 -M were measured using PGE 2 and PGE 2 -M EIA kits from Cayman Chemical.
Results
Structure-activity relationship studies of T34. As shown in Fig. 1 , T34 has three side chain moieties, R 1 , R 2 and R 3 , that could be modified. We designed and synthesized the second generation of this class of compounds by varying the R 1 , R 2 , and R 3 chain length, charge, and aromaticity/aliphaticity. Modification of R 1 and R 3 did not significantly improve affinity (data not shown). However, changes in R 2 profoundly affected the inhibitory activities of the compounds. We therefore focused on further modification of R 2 . The structure-activity relationships of selected second-generation PGT inhibitors are summarized in Table 1 . The percentage inhibition of tracer PGE 2 uptake at 5 μM concentration was calculated as
[(uptake vehicle -uptake inhibitor )/ uptake vehicle ] x 100. Over all, the compounds containing an aromatic benzene ring showed better inhibitory activity than the compounds containing an aliphatic chain in the R 2 moiety. The charge of the group on the aromatic ring had significant impact on inhibitory activity (-OH or -H or -F > -NH 2 ), indicating that positive charge decreases inhibition. Fig. 2 shows the effect of chain length on inhibition. We varied the number of carbons from 0 -10 for the aliphatic R 2 and from 0 -4 for the aromatic R 2 . When R 2 is an aliphatic straight chain ending with a -CH 3 , the inhibition increases as n increases and reaches the highest level at n of 7; thereafter, the inhibition decreases as n increases further ( Fig. 2A ). When R 2 ends with an aromatic benzene, only a benzyl type of substituent, which has one carbon between the benzene ring and the main scaffold, reduces the inhibitory potency dramatically (Fig. 2B ). The inhibitions with n = 0 and 2 carbons between the benzene ring and the main scaffold are almost equal and are higher than all others (Fig. 2B ). When R 2 ends with a phenol group, the inhibition is higher when n = 0 than n = 2 carbons between the benzene ring and the main scaffold ( 2C), implying that -OH enhances inhibition and that rigidity in the R 2 group is in favor of inhibition. These results show that the inhibitory activity is sensitive to the structure of the R 2 moiety, suggesting that R 2 is critical for binding to PGT.
Kinetics of PGT inhibitors.
We next determined the binding constants of the top three inhibitors listed in Table 1 , namely, T26A, T28A, and T25A, by measuring the initial velocities of PGE 2 uptake by PGT at various concentrations of PGE 2 in the presence of various concentrations of one of these inhibitors. We generated K i values and determined the type of inhibition of these inhibitors by fitting Lineweaver-Burk curves, as shown in Fig. 3 . The resulting K i values of these three inhibitors are listed in Table 2 . They all are competitive
has the highest affinity with a K i of 378 nM, a value reasonably close to the binding constant of the substrate PGE 2 to PGT (90 nM) (Kanai, et al., 1995) .
T26A derivatives. Modification of T34 as above had revealed that aromaticity was in favor of inhibition. We therefore increased aromaticity of T26A by replacing the phenol with a naphthol group. As shown in Table 3 , the K i of T26A -1 is slightly higher than that of T26A, suggesting that either the interaction between PGT and the inhibitor does not require aromaticity higher than that possessed by the phenyl ring, or that the potential higher affinity caused by higher aromaticity of the naphthalene ring was cancelled by bulkiness of the naphthalene ring.
Comparison of the best three compounds in Table 2 indicates that -OH on the benzene ring enhances binding affinity. To determine whether the position of -OH mattered, we moved -OH from the para-to the meta position (T26A-2). Table 3 shows that this reduced inhibition.
This article has not been copyedited and formatted. The final version may differ from this version. The -OH of T26A can be either a donor or a receiver of protons. To address this issue, we replaced it with -OCH 3 (T26A-3). The methoxy group of T26A-3 slightly reduced the inhibitory activity compared to T26A, suggesting that this -OH is possibly a proton donor, and therefore the amino acid(s) of PGT that interacts with T26A is possibly a proton receiver.
The native substrates of PGT contain a -COOH at the end of the carbon chain, and PGT functions as an anion transporter (Chan et al., 1998; Chan et al., 2002) . Thus, we hypothesized that adding a -COOH could increase binding to PGT substrate sites as well as increasing water solubility. However, a -COOH did not increase affinity (Table 3) , nor did it affect solubility (data not shown).
Specificity of T26A. For any chemical modulator, specificity is always an issue. PGT is an organic anion transporter and belongs to the larger OATP family (Hagenbuch and Meier, 2004 ). Because it is not feasible to test T26A specificity against all of members of this transporter superfamily, we chose OATPc, which has high homology to PGT (Kanai et al., 1995) . We measured the K i of T26A against this transporter using its substrate sulfobromophthalein (Wang et al., 2003) . The K i of T26A for OATPc is about 10 μM, i.e. almost 30 fold higher than that for PGT, suggesting that T26A has high specificity in favor of PGT as compared to other organic anion transporters.
T26A on COX activity. Another potential concern is whether T26A interacts with components of the PGE 2 signaling pathway involved in PGE 2 production, such as cyclooxygenase1/2 (COX1/2). To directly determine if T26A had any effects on COX activity, we obtained commercially available ovine COX1, ovine COX2, and human recombinant COX2 enzymes and measured PG synthesis upon addition of arachidonic acid (AA) in the absence and presence of various concentrations of T26A. Fig. 4 shows that T26A did not have any significant to PGT, or at a concentration 100-fold higher than the K i of T26A to PGT.
T26A on PGES activity. PGE 2 synthesis also relies on the activity of PGE 2 specific synthases, such as m-PGES. We further determined that T26A did not have significant effect on m-PGES activity (Fig. 5) .
T26A on overall PGE 2 synthesis in MDCK cells in the absence of PGT. As an integrative test of whether T26A affects PGE 2 synthesis, and to confirm the results shown in Fig.   4 and 5, we measured PGE 2 synthesis/release in response to arachidonic acid (AA) addition in WT-MDCK cells (which lack PGT expression), both in the presence and absence of T26A. As shown in Fig. 6 , T26A did not affect PGE 2 synthesis and release at any time point, arguing against any additional T26A effects on m-PGES-2 and/or cytosolic PGES (c-PGES).
Together, these results indicate that T26A is a highly selective inhibitor of PGT, which is the influx step for PGE 2 that is required for PGE 2 intracellular metabolism.
Effects of PGT inhibition on PGE 2 metabolism in cell culture. We next determined whether PGT inhibition with T26A affects the metabolism of PGE 2 generated endogenously in response to bradykinin. We treated either WT-MDCK cells or PGT-MDCK cells with bradykinin and with either vehicle or T26A, and measured extracellular PGE 2 and intracellular PGE 2 -M. In
WT-MDCK cells, the absence of PGT resulted in almost all of the released PGE 2 remaining in the extracellular compartment (Fig. 7A ). Extracellular PGE 2 accumulated as time went on, whereas the amount of PGE 2 -M in the intracellular compartment remained low (Fig. 7B ). In these WT-MDCK cells, T26A did not affect PGE 2 metabolism (Fig. 7, A and B) , as result consistent with the lack of a PGE 2 uptake mechanism in these wild type cells. released medium PGE 2 from the extracellular compartment back into the intracellular compartment and deliver it to 15PGDH for subsequent oxidation to PGE 2 -M (Fig. 7, A and B) .
Thus, extracellular PGE 2 was 2-3 fold lower in PGT-MDCK cells than in WT-MDCK cells, whereas intracellular PGE 2 -M was 2-3 fold higher in PGT-MDCK cells than in WT-MDCK cells (Fig. 7, A and B) . These results are similar to those previously reported from our laboratory (Nomura et al., 2004) . Importantly, T26A almost completely blocked PGE 2 influx and subsequent oxidation,, such that PGE 2 was retained in the extracellular compartment at the levels similar to those in WT-MDCK cells (Fig. 7, A and B).
To determine whether PGT is capable of regulating the metabolism of exogenous PGE 2 , we applied 10 nM exogenous PGE 2 to cells, together with vehicle or T26A. As was the case with T26A on endogenous PGE 2 metabolism, in WT-MDCK cells almost all of the exogenously added PGE 2 remained in the extracellular compartment as intact PGE 2 over 3 hours (Fig. 7, C and D). In contrast, PGT-MDCK cells eliminated 95% of the added PGE 2 from the medium; this resulted in a rise of intracellular PGE 2 -M (Fig. 7, C and D) . With time, extracellular PGE 2 gradually increased whereas intracellular PGE 2 -M gradually decreased, a result of the pumpleak-mediated overshoot of PGE 2 influx as that we have described previously (Chan et al., 1998; Chi et al., 2006) . Of note, T26A was able to abrogate the PGE 2 metabolism due to PGT (Fig. 7, C and D). These results demonstrate that extracellular PGE 2 , even at concentrations much higher than endogenous levels, is rapidly internalized by PGT and is subsequently metabolized to PGE 2 -M, and that this PGE 2 metabolism can be effectively prevented by inhibiting PGT with T26A.
T26A on PGE 2 metabolism in vivo. Endogenous and exogenous PGE 2 are nearly completely metabolized in a single passage through the lung (Ferreira and Vane, 1967; Piper et al., 1970; Dawson et al., 1975; Schuster, 1998) , and PGT is very strongly expressed in the lung 16 (Kanai et al., 1995; Lu et al., 1996; Pucci et al., 1999) . To assess the ability of T26A to block PGE 2 metabolism in vivo, we injected vehicle/T26A into the jugular vein of rats and withdrew blood via the carotid artery. Fig. 8A shows that the arterial concentration of endogenous PGE 2 in anaesthetized rats injected intravenously with T26A peaked at more than 200% that of rats injected with vehicle. Conversely, the concentration of endogenous arterial PGE 2 -M was reduced 50% by intravenous T26A (Fig. 8B) . T26A also slowed the elimination of exogenously-added PGE 2 . As shown in Fig. 8C , compared to rats previously injected with vehicle alone, those injected with T26A achieved a 3-4 fold higher arterial PGE 2 concentration after an intravenous PGE 2 injection. In accord with these results, the concentration of arterial PGE 2 -M was 3-4 fold lower in T26A-treated rats compared to that of vehicle-treated controls.
This article has not been copyedited and formatted. The final version may differ from this version. (Ferreira and Vane, 1967) . . Subsequently, work by Bito et al, Eling et al, and others demonstrated that PGE 2 added to the perfusate of the isolated, perfused lung or kidney disappears within 5 minutes and re-appears as the 15-keto-PGE 2 metabolite in the perfusion collections. These groundbreaking early studies further revealed that, when bromcresol green, a non-specific organic anion transport inhibitor, was applied to the perfusion system, PGE 2 appeared intact in the perfusion collections, suggesting that PGE 2 metabolism was dependent on its transport Bito and Baroody, 1975; Bito, 1976b; Bito et al., 1976c; Bito et al., 1977; Dawson et al., 1975 ; ). These earlier studies are consistent with the present data as presented in Figure 7 , C and D, namely, MDCK cells (which express 15PGDH (Nomura et al, 2005) ) that have been engineered to also express a PGE 2 uptake carrier (PGT) convert PGE 2 to the 15-keto metabolite.
Despite this extensive prior literature, the molecular mechanism of PG transport, and its role in regulating PG signal termination, have been appreciated only recently. We molecularly identified the prostaglandin transporter PGT (Kanai et al., 1995) and postulated that it is responsible for PGE 2 uptake prior to enzymatic oxidation (Schuster, 1998; Schuster, 2002) . We have previously shown in culture cells that PGT is critical for PGE 2 metabolism (Chang et al., 2010) , since PGT-mediated PGE 2 re-uptake is the main pathway for PGE 2 influx (Chi and Schuster, 2010) and is a prerequisite for PGE 2 intracellular metabolism (Nomura, et al., 2004) .
We have also reported that adult mice rendered null at the PGT locus have elevated systemic (urinary) PGE 2 levels and lowered plasma PGE 2 metabolite levels compared to wild type mice (Chang et al., 2010) , indicating that PGT plays an important role in regulating PG levels in the circulation. That said, since in those genetic studies PGT was knocked out from the single cell stage, those studies did not allow us to determine whether the increased PGE 2 in plasma was a direct result of PGT deletion, or rather was due to one or more biological modulation(s) that resulted indirectly from PGT deletion, . The fact that pharmacological inhibition of PGT with T26A in the present experiments increased plasma PGE 2 within several minutes (Fig. 8) indicates that PGT does, indeed, directly modulate extracellular PGE 2 levels. The present results also suggest that pharmacological PGT inhibition is a powerful tool for studying the biological roles of PGT.
The SAR studies described in this report allowed us to obtain an inhibitor, T26A, that is 10-fold more potent than it precursor (Chi et al., 2006) . There is some structural resemblance between T26A and PGE 2 (Fig. 1, B and C). R 2 of T26A resembles the five-member ring in PGE 2 . The -OH on the ring of PGE 2 is important for binding, and it is likely to be a proton donor, rather than a receiver (Chi et al., 2010) . Similarly, the -OH of R 2 is important for binding and is likely to be a proton donor because T26A binds to PGT stronger than T26A-3 does (Table   3 ). R 1 and R 3 possibly resemble the two acyl chains of PGE 2 . In this regard, replacing the -OH group of R 2 with a -COOH did not improve affinity ( Table 3 ), suggesting that a -COOH in the end of either R 1 or R 3 could possibly improve solubility without adversely affecting affinity.
The results of SAR studies of T34 and T26A provide a basis for speculating about the binding site of PGT. T34 has three moieties, only one of which, R 2 , is sensitive to inhibition, suggesting that PGT possibly has only one binding site for its substrates. The present studies suggest that the amino acid(s) of PGT that binds to the substrates is probably positively charged, since a negative charge on the inhibitor site increases affinity (Table 1) . These results are in accord with our previous studies demonstrating that PGT is inhibited by disulfonic stilbenes, niflumic acid, and the thiol reactive anion MTSES (Na(2-sulfonatoethyl)methanethiosulfonate) (Chan et al.,1998) ; by our cysteine-scanning mutagenesis and molecular modeling of putative transmembrane 10, which indicated that the substrate binding of PGT is formed among its membrane-spanning segments, with 4 residues along the cytoplasmic end of helix 10 contributing to one surface of the binding site ; and by our site-directed mutagenesis studies indicating a critical role for arginine 560 in substrate translocation .
In addition, we hypothesize that the docking pocket for T26A probably has limited space to accommodate a substrate, since replacing phenol with naphthol did not increase the affinity (Table 3) , even though naphthol has higher aromaticity than phenol, which is presumably in favor of binding (Table 1 ).
All small-molecule inhibitors suffer from possible lack of specificity. We have addressed the issue of specificity by examining the affinity of T26A for a closely related gene family member, OATPc (SLCO1B1) that has high homology with PGT (Kanai et al., 1995) . SLCO1B1
is a particularly relevant homologue for this study because it mediates the hepatic uptake of various drugs, including most statins and statin acids (König et al., 2006) , and because genetic variations in the SLCO1B1 gene have been associated with both statin-associated myopathy and reductions in the lipid-lowering effect of statins (Link et al., 2008) . The 10-fold weaker binding of T26A to OATPc compared to PGT suggests that T26A is a selective inhibitor of PGT within the OATP gene family.
In addition, we determined whether T26A directly interacted with synthases of PGE 2 .
Insignificant effects of T26A on the activities of COX1, COX2 and m-PGES (Figs. 4 and 5) eliminated the concern that increased PGE 2 by T26A could be due to activation of those synthases. This was further confirmed by the fact that T26A did not affect overall PGE 2 production in cells that did not express PGT (Fig. 6) . That T26A does not affect PGE 2 synthesis is also supported by the in vivo data showing that endogenous serum PGE 2 levels were more than doubled within short period of time (15 minutes) after T26A injection (Fig. 8A ).
Besides being a powerful basic research tool for investigating the fundamental role of Legends for Figures   Fig. 1 . Structures of PGE 2 , and PGT inhibitors T34 and T26A. 
